Skip to main content

Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial (2020)
Journal Article
Smith, J. A., Kitt, M. M., Morice, A. H., Birring, S. S., McGarvey, L. P., Sher, M. R., …Ford, A. P. (in press). Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial. The lancet. Respiratory medicine, https://doi.org/10.1016/S2213-2600%2819%2930471-0

Background: Gefapixant is a P2X3 receptor antagonist in development for treatment of refractory (RCC) and unexplained chronic cough (UCC). Methods: We conducted a 12-week, Phase 2b, randomized, double-blind, placebo-controlled study in patients w... Read More about Gefapixant A P2X3 Receptor Antagonist For The Treatment Of Refractory Or Unexplained Chronic Cough In A Phase 2b Randomised Controlled Trial.


;